AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 201 filers reported holding AGIOS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,179,451 | -9.7% | 451,695 | +3.3% | 0.00% | -25.0% |
| Q2 2023 | $12,383,628 | +25.4% | 437,275 | +1.7% | 0.00% | +33.3% |
| Q1 2023 | $9,872,782 | -18.2% | 429,812 | +0.0% | 0.00% | -25.0% |
| Q4 2022 | $12,068,082 | +1.5% | 429,775 | +2.2% | 0.00% | 0.0% |
| Q3 2022 | $11,894,000 | +37.0% | 420,563 | +7.4% | 0.00% | +33.3% |
| Q2 2022 | $8,682,000 | -24.5% | 391,586 | -0.9% | 0.00% | 0.0% |
| Q1 2022 | $11,506,000 | -9.2% | 395,248 | +2.5% | 0.00% | -25.0% |
| Q4 2021 | $12,676,000 | -33.1% | 385,635 | -6.1% | 0.00% | -33.3% |
| Q3 2021 | $18,950,000 | -8.4% | 410,601 | +9.3% | 0.01% | -14.3% |
| Q2 2021 | $20,695,000 | +44.7% | 375,506 | +35.6% | 0.01% | +40.0% |
| Q1 2021 | $14,301,000 | +23.8% | 276,927 | +3.9% | 0.01% | 0.0% |
| Q4 2020 | $11,554,000 | +25.4% | 266,631 | +1.3% | 0.01% | +25.0% |
| Q3 2020 | $9,215,000 | -38.0% | 263,265 | -5.3% | 0.00% | -42.9% |
| Q2 2020 | $14,863,000 | +67.2% | 277,902 | +10.9% | 0.01% | +40.0% |
| Q1 2020 | $8,889,000 | -29.1% | 250,513 | -4.5% | 0.01% | -28.6% |
| Q4 2019 | $12,530,000 | +66.2% | 262,389 | +12.8% | 0.01% | +75.0% |
| Q3 2019 | $7,538,000 | -28.8% | 232,636 | +9.6% | 0.00% | -33.3% |
| Q2 2019 | $10,591,000 | -24.8% | 212,321 | +1.7% | 0.01% | -33.3% |
| Q1 2019 | $14,085,000 | +66.2% | 208,844 | +13.6% | 0.01% | +50.0% |
| Q4 2018 | $8,475,000 | -39.9% | 183,792 | +0.6% | 0.01% | -33.3% |
| Q3 2018 | $14,093,000 | -0.1% | 182,731 | +9.1% | 0.01% | -10.0% |
| Q2 2018 | $14,109,000 | +13.6% | 167,503 | +10.3% | 0.01% | 0.0% |
| Q1 2018 | $12,416,000 | +78.0% | 151,812 | +24.5% | 0.01% | +66.7% |
| Q4 2017 | $6,974,000 | -9.9% | 121,975 | +5.2% | 0.01% | -14.3% |
| Q3 2017 | $7,743,000 | +55.4% | 115,995 | +19.7% | 0.01% | +40.0% |
| Q2 2017 | $4,984,000 | +2.4% | 96,866 | +16.2% | 0.01% | 0.0% |
| Q1 2017 | $4,867,000 | +53.1% | 83,327 | +9.4% | 0.01% | +66.7% |
| Q4 2016 | $3,179,000 | +3.6% | 76,169 | +31.1% | 0.00% | -25.0% |
| Q3 2016 | $3,068,000 | +36.5% | 58,081 | +8.3% | 0.00% | +33.3% |
| Q2 2016 | $2,247,000 | +20.8% | 53,619 | +17.0% | 0.00% | +50.0% |
| Q1 2016 | $1,860,000 | -45.5% | 45,811 | -12.8% | 0.00% | -60.0% |
| Q4 2015 | $3,412,000 | -3.9% | 52,547 | +4.5% | 0.01% | 0.0% |
| Q3 2015 | $3,550,000 | +55.7% | 50,289 | +145.2% | 0.01% | +66.7% |
| Q2 2015 | $2,280,000 | -34.4% | 20,507 | -44.4% | 0.00% | -40.0% |
| Q1 2015 | $3,478,000 | -10.3% | 36,872 | +6.6% | 0.01% | -16.7% |
| Q4 2014 | $3,877,000 | +148.7% | 34,599 | +36.2% | 0.01% | +100.0% |
| Q3 2014 | $1,559,000 | +35.6% | 25,399 | +1.2% | 0.00% | +50.0% |
| Q2 2014 | $1,150,000 | +94.6% | 25,098 | +66.3% | 0.00% | +100.0% |
| Q1 2014 | $591,000 | +67.4% | 15,094 | +2.4% | 0.00% | 0.0% |
| Q4 2013 | $353,000 | -14.3% | 14,734 | +3.0% | 0.00% | 0.0% |
| Q3 2013 | $412,000 | – | 14,302 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |